Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network

J Med Imaging (Bellingham) 2020 Deep Learning 6 Explanations View Original
Original Paper (PDF)

Unable to display PDF. Download it here or view on PMC.

Plain-English Explanations
Pages 1-2
Grading Prostate Cancer Through Tissue Structure

Prostate cancer is graded using the Gleason scoring system, which evaluates how much the cancer tissue has lost its normal glandular architecture. Higher Gleason scores indicate more disorganized tissue and predict more aggressive behavior. This grading relies on visually identifying specific tissue features, particularly the arrangement of stroma (supportive connective tissue), epithelium (the gland-lining cell layer), and lumen (the hollow space inside glands) -- collectively abbreviated as SEL.

In a healthy prostate, glands have a clear structure: an inner hollow space (lumen) surrounded by a ring of epithelial cells, embedded in stroma. As cancer progresses, glands become progressively more distorted, fused, or absent. Quantifying these architectural changes -- called histomorphometry -- can provide objective, reproducible cancer grading.

Automated SEL segmentation would enable consistent large-scale grading of digital pathology slides, but existing computational methods are brittle. Rule-based algorithms that use fixed intensity thresholds break down when slides are stained slightly differently or scanned on different equipment, and their errors compound in downstream cancer classification pipelines.

Deep learning offers a more flexible approach, but it typically requires large numbers of precisely labeled training images. Annotating every pixel in a tissue slide as stroma, epithelium, or lumen is extremely time-consuming for expert pathologists. This study asks whether weak supervision -- using imperfect, computer-generated labels to train a neural network -- can bridge this gap.

TL;DR: Prostate cancer grading relies on evaluating glandular tissue architecture, and this study tests whether weakly labeled deep learning can accurately segment the three key tissue components needed for automated grading.
Pages 2-5
Weak Labels, Strong Labels, and Three Training Arms

The study used biopsy core images from 145 patients at the University of Wisconsin and whole-mount prostate slides from 26 patients at the Medical College of Wisconsin. Two types of ground truth labels were created for the biopsy cores. Human-generated (HG) strong labels were produced by a trained observer who manually outlined each tissue class pixel-by-pixel on 16 images using a tablet stylus -- highly accurate but very time-consuming.

Morphologically generated (MG) weak labels were produced by a custom automated algorithm using color thresholding and intensity analysis in MATLAB -- fast (under one second per image) but prone to errors, particularly in distinguishing lumen from epithelium in complex glandular regions.

Three training configurations (Arms) were tested using the same neural network architecture (SegNet, an encoder-decoder deep learning architecture). Arm 1 trained exclusively on the large MG dataset (140 weakly labeled images). Arm 2 trained exclusively on the small HG dataset (10 expertly labeled images). Arm 3 trained first on the large MG dataset (coarse phase), then fine-tuned on the small HG dataset (precision phase).

Each arm was evaluated against the human-labeled test set, ensuring all comparisons were made against the highest-quality ground truth. A fourth configuration (mArm) combined the outputs of all three arms, with epithelium labels taking priority, reflecting its central importance in Gleason grading.

TL;DR: Three neural network training configurations -- weak labels only, strong labels only, and weak followed by strong (fine-tuning) -- were compared to determine the best strategy for tissue segmentation using limited expert annotations.
Pages 4-5
Color Normalization and the SegNet Architecture

A significant practical challenge in digital pathology is that tissue slides stained and scanned at different institutions look visually different even when the same staining protocol is used. To address this, all images underwent color deconvolution -- a technique that mathematically separates the hematoxylin (blue, staining cell nuclei) and eosin (pink, staining cytoplasm and connective tissue) dye contributions into separate image channels.

Whole-mount slides from a different institution were additionally color normalized to a reference biopsy image before processing, reducing cross-site staining variability. This preprocessing step is essential for any model expected to work across different labs or scanners.

SegNet is an encoder-decoder neural network architecture originally developed for scene understanding in photographs. It uses an encoding pathway to extract progressively abstract features and a mirrored decoding pathway to reconstruct a pixel-by-pixel classification map. Transfer learning from VGG16 (a network pre-trained on a large natural image database) was used to initialize the weights, accelerating training and improving performance on the relatively small pathology dataset.

Training was conducted in three phases per arm: an initial high-learning-rate rough-in phase, a longer plateau phase with reduced learning rate, and a final fine-tuning phase with a very low learning rate. This multi-phase approach is standard practice for adapting pre-trained networks to new domains.

TL;DR: SegNet was pre-trained on natural images and fine-tuned on color-normalized H&E pathology tiles, with separate training phases for coarse feature learning and precision refinement.
Pages 7-9
Combining Weak and Strong Labels Gives Best Performance

Arm 3 (trained first on weak MG labels, then fine-tuned on strong HG labels) achieved the best overall segmentation performance across all three tissue classes. ROC AUC scores for Arm 3 were: stroma 0.94, epithelium 0.94, and lumen 0.92 -- statistically significantly better than both Arm 1 and Arm 2 alone (two-way ANOVA, p less than 0.01).

Arm 2 (small expert-labeled dataset only) notably failed to segment lumen at all -- its probability maps for lumen and epithelium overlapped so heavily that the network could not distinguish between them. This illustrates the danger of using too few examples: even with high-quality labels, the model cannot generalize from insufficient sample sizes.

Arm 1 (large weakly labeled dataset only) was better at lumen detection but produced noisier, less accurate labels overall -- confirming that noisy training data has limits. Crucially, however, the deep learning model trained on noisy MG labels still outperformed the MG algorithm itself on the same test set, demonstrating that the neural network distilled genuine biological features rather than merely memorizing the noisy training labels.

The consistency improvement was also measurable: SEL labels from all deep learning arms showed significantly lower variance than MG labels on the same tissue regions (Bartlett test p less than 0.001), meaning the neural network produced more reproducible results than the rule-based algorithm it learned from.

TL;DR: Training first on large weakly labeled data then fine-tuning on small expertly labeled data (Arm 3) achieved the highest tissue segmentation accuracy, and the neural network outperformed its own noisy training labels.
Pages 9-11
Improved Cancer Detection Through Better Tissue Analysis

The practical value of better SEL segmentation was tested by applying the combined mArm classifier to whole-mount prostate slides containing both benign abnormalities (atrophy, high-grade PIN) and Gleason 3+ cancerous regions, then comparing how well SEL-based tissue signatures could distinguish cancer from benign tissue.

A support vector machine (SVM) classifier was trained to distinguish benign versus cancerous regions using only the SEL percentage signature of each annotated region -- the relative proportion of stroma, epithelium, and lumen -- as features. Using mArm-derived SEL features, the SVM achieved 86.49% accuracy in cancer classification. Using MG-derived SEL features, accuracy fell to 77.14% (p = 0.002).

This nearly 10-percentage-point improvement in cancer classification accuracy -- achieved solely by improving the quality of the tissue segmentation inputs -- demonstrates that better SEL quantification directly translates into clinically meaningful improvements in automated cancer detection.

Importantly, the biopsy-trained model generalized well to whole-mount slides from a separate institution with different staining and scanning equipment, demonstrating cross-institutional robustness -- an essential requirement for any AI tool intended for widespread clinical deployment.

TL;DR: Better tissue segmentation from the deep learning model raised automated cancer-versus-benign classification accuracy from 77% to 86%, demonstrating that improved SEL analysis directly translates into better clinical cancer detection.
Pages 11-12
Lessons for Scaling AI in Pathology

This study provides a practical roadmap for training deep learning models in data-scarce pathology settings. The key finding is that combining large weakly labeled datasets with small expertly labeled fine-tuning data reliably outperforms either approach used alone, and consistently outperforms the original weak labeling algorithm the network was trained on.

This matters because expert pathologist annotation time is the primary bottleneck for building medical AI training datasets. If existing rule-based algorithms can generate imperfect but usable starting labels, and a small number of expert corrections are sufficient to refine performance, the cost of creating training data drops dramatically.

The authors envision the trained algorithm being used as part of multi-stage cancer detection pipelines, as a decision support tool offering a second opinion in computer-aided diagnosis systems, or as a generator of higher-level tissue metrics such as epithelial thickness and gland tortuosity that better capture Gleason grading criteria in a quantitative way.

Future work will focus on expanding dataset size, incorporating deformable tissue compartments into the segmentation scheme, and testing performance across a broader range of Gleason grades and patient populations to move toward a fully automated, validated cancer detection pipeline.

TL;DR: Using imperfect computer-generated labels to pre-train and expert annotations to fine-tune a neural network is a scalable and effective strategy for advancing AI-based prostate cancer tissue analysis.
Citation: Open Access, . Available at: PMC7550797.